Vaccine manufacturer Bharat Biotech has received approval to conduct Phase-III clinical trials of an intranasal booster dose on people who have received both doses of Covaxin. The Drug Controller General of India today gave the go-ahead for the Phase-III trials. The trials will be conducted at nine locations in the country.